Dapadrift M 5/500mg Tablet

DAPADRIFT M 5/500 mg Tablet is a fixed-dose combination of two oral antidiabetic agents:

• Dapagliflozin (5 mg): A Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion.

• Metformin (500 mg): A Biguanide that reduces hepatic glucose production and improves insulin sensitivity.

Together, they offer a complementary approach to managing Type 2 Diabetes Mellitus (T2DM) in adults.

USES

• Treatment of Type 2 Diabetes Mellitus (T2DM) in adults

• Used when diet, exercise, and monotherapy do not provide adequate blood sugar control

• May also help in reducing cardiovascular risks and slowing the progression of diabetic kidney disease in certain patients

BENEFITS

• Dual mechanism of action for effective glycemic control:

  • Dapagliflozin: Removes excess glucose via urine

  • Metformin: Lowers liver glucose production and improves insulin sensitivity

• Low risk of hypoglycemia (when not combined with insulin or sulfonylureas)

• Potential weight loss benefit (due to dapagliflozin)

• May provide cardiovascular and renal benefits in eligible patients

• Improved treatment adherence through a single-pill regimen

• Better tolerability in patients starting metformin therapy at a lower dose

SIDE EFFECTS

Common Side Effects:

• Increased urination

• Genital fungal infections (especially in females)

• Nausea, vomiting, or diarrhea (mainly due to Metformin)

• Headache

• Urinary tract infections

Less Common / Serious Side Effects:

• Lactic acidosis (rare but serious; associated with Metformin, especially in renal impairment)

• Diabetic ketoacidosis (rare but serious; associated with SGLT2 inhibitors)

• Dehydration or hypotension

• Hypoglycemia (more likely when used with insulin or sulfonylureas)

• Allergic reactions (rash, itching, or swelling)